POS1278 SAFETY AND PHARMACOKINETICS OF IGPRO20 (SUBCUTANEOUS IMMUNOGLOBULIN) AND IGPRO10 (INTRAVENOUS IMMUNOGLOBULIN) IN ADULTS WITH SYSTEMIC SCLEROSIS (SSC) – RESULTS FROM A PHASE 2 TRIAL - Denton, C. P.; Kowal-Bielecka, O.; Proudman, S.; Olesińska, M.; Worm, M.; Del Papa, N.; Matucci-Cerinic, M.; Radewonuk, J.; Jochems, J.; Shebl, A.; Krupa, A.; Hofmann, J.; et al. (Annals of the rheumatic diseases, 2023)
Keywords: Bioavailability; Body weight; Breast cancer; Chronic infection; Clinical trials; COVID-19; Dehydration; Diarrhea; Gastritis; Heart attacks; Hemorrhage; Immunodeficiency; Immunoglobulin G; Immunoglobulins; Intravenous administration; Ischemia; Lung cancer; Lung diseases; Myocardial infarction; Myocardial ischemia; Pain; Pharmacokinetics; Primary immunodeficiencies; Respiratory function; Safety; Scientific Abstracts; Scleroderma; Stockholders; Systemic sclerosis; Vomiting; Clinical trials; Systemic sclerosis; Safety